Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597852 | 0.94 | OPRD1 (0.70) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6599148 | 0.87 | OPRD1 (0.61) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6598567 | 0.86 | OPRD1 (0.79) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6602339 | 0.86 | OPRD1 (0.62) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6602593 | 0.86 | OPRD1 (1.00) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6599737 | 0.85 | OPRD1 (0.63) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6599219 | 0.83 | OPRD1 (0.56) | OPRD1OPRK1OPRM1 | |
| SCHEMBL7671965 | 0.82 | OPRD1 (0.73) | OPRD1OPRK1OPRM1DRD3 | |
| SCHEMBL6598877 | 0.82 | OPRD1 (0.89) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6600476 | 0.81 | OPRD1 (0.55) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140835-B1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PROD INC (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | PFIZER INC | 2004-04-01 | — | — | US | disclosed |
| US-6586431-B1 | Treating drug abuse and drug dependence; nervous system and gastrointestinal disorders | PFIZER INC | 2003-07-01 | — | — | US | disclosed |
| US-6503905-B1 | Treating nervous system and gastrointestinal disorders; analgesics, antiasthmatics | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | BCHE, HTR3C, CHRM2 | OPRD1 24/4885OPRK1 39/4885OPRM1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.